HHS is reviving a 340B rebate push after a previous pilot was blocked in court, according to coverage of the administrative change. Providers said the approach would increase administrative and financial burden for already cash-strapped institutions. Separately, a continuing resolution in the U.S. Senate would delay implementation of OMB rule changes tied to federal research grant reviews, with critics warning that the changes would increase political control over which grants get funded. Finally, Arkansas will not enforce its Act 630 on drug distribution following a federal court ruling likely deeming the measure unconstitutional, with concerns raised that limited distribution networks could collide with FDA REMS and patient-safety requirements. Taken together, the updates show fast-moving federal and state pressure points spanning rebate policy, research funding governance, and distribution network rules—issues that directly affect how therapies reach patients and how quickly biomedical programs can progress.